In the pivotal gilteritinib versus salvage chemotherapy (ADMIRAL) trial in 371 patients with FLT3-mutated AML, Perl and colleagues164 reported on 51 patients achieving a response post gilteritinib and undergoing allogeneic SCT who either resumed gilteritinib post SCT (n = 35) or did not (n = 16). The gene discussed is FLT3; the disease is acute myeloid leukemia.